Abstract

Lethal systemic fungal infections of Candida species are increasingly common, especially in immune compromised patients. By in vitro screening of small molecule mimics of naturally occurring host defense peptides (HDP), we have identified several active antifungal molecules, which also exhibited potent activity in two mouse models of oral candidiasis. Here we show that one such compound, C4, exhibits a mechanism of action that is similar to the parent HDP upon which it was designed. Specifically, its initial interaction with the anionic microbial membrane is electrostatic, as its fungicidal activity is inhibited by cations. We observed rapid membrane permeabilization to propidium iodide and ATP efflux in response to C4. Unlike the antifungal peptide histatin 5, it did not require energy-dependent transport across the membrane. Rapid membrane disruption was observed by both fluorescence and electron microscopy. The compound was highly active in vitro against numerous fluconazole-resistant clinical isolates of C. albicans and non-albicans species, and it exhibited potent, dose-dependent activity in a mouse model of invasive candidiasis, reducing kidney burden by three logs after 24 hours, and preventing mortality for up to 17 days. Together the results support the development of this class of antifungal drug to treat invasive candidiasis.

Highlights

  • Lethal systemic fungal infections of Candida species are increasingly common, especially in immune compromised patients

  • It has been suggested that the initial interaction between AMPs and the microbial membrane is an electrostatic interaction between the cationic residues and the anionic headgroups found predominantly on microbial membranes[28]

  • As systemic Candida infections are often fatal, and both C. albicans and non-albicans species (NAC) species are rapidly developing resistance to standard antifungal treatments, it is essential to develop novel antifungal agents which act via mechanisms that make it difficult to develop resistance

Read more

Summary

Introduction

Lethal systemic fungal infections of Candida species are increasingly common, especially in immune compromised patients. A subsequent screen of the library led to the identification of several new compounds with potent anti-fungal activity in vitro against both yeast and hyphal forms, low cytotoxicity to human cells, and strong in vivo activity in two different mouse models of oral candidiasis[25]. We extend these studies to elucidate the mechanism of action and to quantify the activity of one of these lead compounds, compound 4 We demonstrate its in vivo activity in a mouse model of invasive candidiasis

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call